GGrantIndex
Sort

21,453 grants matching tuberculosis

Center to develop therapeutic countermeasures to high-threat bacterial agents

$5,504,272
David S Perlin · Rbhs-New Jersey Medical School · U19 · FY2016 · AI

Infectious Disease Genomics: Pathogen Evolution, Emergence, and Host Interaction

$5,496,338
Bruce W. Birren · Broad Institute, Inc. · U19 · FY2018 · AI

Emory- Duke- Orlando- CDC (EmDOC) Clinical Trials Unit

$5,493,765
Jeffrey Lennox · Emory University · UM1 · FY2019 · AI

Development of Adjuvant with Vaccines for Tuberculosis and Shigellosis

$5,490,179
Kathlenn Kozar · Tulane University · N01 · FY2013 · AI

Modulation of Protein production and Degradation as an integrated approach to rapid sterilization of Drug sensitive and resistant Mtb.

$5,485,460
Nader Fotouhi · Global Alliance For Tb Drug Development · U19 · FY2019 · AI

Vaccine and Treatment Evaluation Units

$5,485,363
Nadine Georges Rouphael · Emory University · UM1 · FY2020 · AI

Modulation of Protein production and Degradation as an integrated approach to rapid sterilization of Drug sensitive and resistant Mtb.

$5,472,466
Nader Fotouhi · Global Alliance For Tb Drug Development · U19 · FY2023 · AI

Studies of Medical Radiation and Other Therapeutic Agents

$5,452,871
Amy Berrington · Division Of Cancer Epidemiology And Genetics · ZIA · FY2009 · CA

Infectious Disease Genomics: Pathogen Evolution, Emergence, and Host Interaction

$5,445,286
Bruce W. Birren · Broad Institute, Inc. · U19 · FY2014 · AI

Immune Mechanisms of Protection Against Mycobacterium Tuberculosis Center (IMPAC-TB)

$5,443,065
Kevin Urdahl · Seattle Children'S Hospital · N01 · FY2024 · AI

SDMC: HIV Vaccine Trials Network

$5,436,127
Peter B. Gilbert · Fred Hutchinson Cancer Research Center · UM1 · FY2022 · AI

Regional Prospective Observational Research in Tuberculosis (RePORT) International Coordinating Center (RICC) (RePORT RICC)

$5,400,000
Michael Dignam · National Institute Of Allergy And Infectious Diseases · Y01 · FY2020 · AI

Center to develop therapeutic countermeasures to high-threat bacterial agents

$5,399,115
David S Perlin · Rbhs-New Jersey Medical School · U19 · FY2014 · AI

COOPERATIVE AGREEMENT WITH THE KENYA MEDICAL RESEARCH INSTITUTE (KEMRI)

$5,347,112
John Vulule · Kenya Medical Research Institute (Kemri) · U19 · FY2013 · GH

Southwest National Primate Research Center

$5,329,661
Southwest Foundation For Biomedical Res · P51 · FY2005 · RR

STRUCTURAL ORGANIZATION AND PROTEOMICS OF TB

$5,274,660
University Of Calif-Los Alamos Nat Lab · P50 · FY2001 · GM

Center to develop therapeutic countermeasures to high-threat bacterial agents

$5,254,272
David S Perlin · Rbhs-New Jersey Medical School · U19 · FY2015 · AI

University of North Carolina Global HIV Prevention and Treatment Clinical Trials

$5,246,488
Joseph J. Eron · Univ Of North Carolina Chapel Hill · UM1 · FY2020 · AI

Simian Vaccine Evaluation Unit (SVEU)

$5,229,662
Phillip D Markham · Advanced Bioscience Laboratories, Inc. · N01 · FY2010 · AI

Laboratory for Combinatorial Drug Regimen Design for Resistant and Emerging Pathogens

$5,147,109
Linden T Hu · Tufts University Boston · C06 · FY2022 · OD

CoVPN - COVID Countermeasures

$5,088,428
Ann R Falsey · University Of Rochester · UM1 · FY2020 · AI

Identification of novel Th17 inducing CTLR agonists for vaccines against mycobacterium tuberculosis

$5,082,137
Jay Evans · Corixa Corporation · N01 · FY2014 · AI

IMPACTA PERU CLINICAL TRIALS UNIT

$5,080,925
Javier R Lama · Asociacion Civil Impacta Salud Y Educacn · UM1 · FY2019 · AI

TUBERCULOSIS ELIMINATION AND LABORATORY COOPERATIVE AGREEMENT

$5,079,101
Joseph Burzynski · New York City Health/Mental Hygiene · U52 · FY2014 · PS

Infectious Disease Genomics: Pathogen Evolution, Emergence, and Host Interaction

$5,063,540
Bruce W. Birren · Broad Institute, Inc. · U19 · FY2017 · AI